Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuronox in Idiopathic Overactive Bladder
NCT04113941Phase 3Unknown
- Sponsor
- Medytox Inc.
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing Neuronox with Placebo (2 arms). Primary endpoint: Change in the daily average Urinary Incontinence (UI) episodes at 12 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04113941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113941.